MedPath

Noninterventional Study Evaluating Parkinson's Disease Diary Use

Active, not recruiting
Conditions
Parkinson's Disease
Registration Number
NCT05363046
Lead Sponsor
BlueRock Therapeutics
Brief Summary

This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.

Detailed Description

This is a global, multi-center, noninterventional study of patients with PD aged ≥39 to ≤70 years under standard-of-care treatment that will enroll a minimum of approximately 150 participants and up to 400 participants. Participants will be assigned (1:1) to complete the PD diary either on 3 consecutive days in 1 week (Group A) or 2 consecutive days in each of 2 consecutive weeks (Group B) for a given study visit. During the study, data are collected on motor function, quality of life, and use of PD medications at Baseline and at 3, 6, 12, 18, and 24 months.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
194
Inclusion Criteria

Not provided

Exclusion Criteria
  • PD with risk of recurrent falls or only tremor-based symptoms
  • Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis, or clinical features suggestive of a neurodegenerative disease other than PD such as Alzheimer's disease
  • Any available evidence inconsistent with dopamine deficiency (eg, 18F-DOPA positron emission tomography [PET] or dopamine transporter single-photon emission computed tomography [DAT-SPECT] imaging if performed)
  • Moderately severe dyskinesia per investigator's judgment
  • Receiving dopamine receptor-blocking agents, including typical neuroleptics, prochlorperazine, and metoclopramide at the time of screening or within 3 months prior to screening
  • Treatment with intrajejunal or subcutaneous infusion therapies for PD within 2 months of screening
  • History of gene therapy or cell therapy
  • Prior surgical or radiation therapy to the brain, including deep brain stimulation and lesion therapy, or prior history of intradural spinal cord surgery
  • Receipt of another investigational therapy or device within 2 years of screening unless approved by the medical monitor

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Good ON-time as measured by the PD Diary.Baseline, 3, 6, 12, 18 and 24 months.

Standard deviation of change in ON-time without troublesome dyskinesia (Good ON-time) as measured by the PD diary.

Individual participant variability for ON-time without troublesome dyskinesia (Good ON-time) as measured by the PD diary.Baseline, 3, 6, 12, 18 and 24 months.

Within-subject coefficient of variation for ON-time without troublesome dyskinesia (Good ON-time) as measured by the PD diary.

Proportion of valid PD Diaries.Baseline, 3, 6, 12, 18 and 24 months.

Proportion of valid PD Diaries.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (34)

University of Miami Health System

🇺🇸

Miami, Florida, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

Mayo Clinic Neurology

🇺🇸

Scottsdale, Arizona, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

David Geffen School of Medicine University of California Los Angeles

🇺🇸

Los Angeles, California, United States

Parkinson's Disease and Movement Disorders Center at Northwestern University Feinberg School of Medicine

🇺🇸

Chicago, Illinois, United States

University of California, Irvine

🇺🇸

Orange, California, United States

Movement Disorders Center of Boca Raton

🇺🇸

Boca Raton, Florida, United States

University of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Evergreen Health Medical Center

🇺🇸

Kirkland, Washington, United States

Dkd Wiesbaden

🇩🇪

Wolfach, Baden-Württemberg, Germany

Toronto Western Hospital

🇨🇦

Toronto, Ontario, Canada

Klinikum der Universität München - Campus Grosshadern

🇩🇪

Munich, Bayern, Germany

Universitätsklinikum Würzburg - Medizinische Klinik

🇩🇪

Würzburg, Bayern, Germany

Technischen Universitaet Muenchen (TUM)

🇩🇪

Munich, Bayern, Germany

Klinik und Poliklinik für Neurologie am Standort Marburg

🇩🇪

Marburg, Hessen, Germany

Universitätsmedizin Rostock

🇩🇪

Rostock, Germany

Universitaetsklinikum Duesseldorf AöR

🇩🇪

Düsseldorf, Germany

University Hospital Tuebingen

🇩🇪

Tübingen, Germany

AOU Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi

🇮🇹

Ancona, Italy

Azienda Ospedale Università Padova

🇮🇹

Padova, Italy

IRCCS San Raffaele Pisana

🇮🇹

Rome, Italy

Hospital San Juan de Dios

🇪🇸

Santurtzi, Bilbao, Spain

Complexo Hospitalario de Pontevedra (CHOP)

🇪🇸

Pontevedra, Spain

Hospital de la Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

AOU OO.RR. San Giovanni di Dio Ruggi d'Aragona

🇮🇹

Salerno, Italy

Hospital Universitario Virgen del Rocio

🇪🇸

Sevilla, Spain

Hospital Universitario Y Politécnico La Fe

🇪🇸

Valencia, Spain

Weill Cornell Medicine - New York Presbyterian Hospital

🇺🇸

New York, New York, United States

Mount Sinai West

🇺🇸

New York, New York, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath